ArticleHarm reduction journal2022
Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20).
Article in Harm reduction journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 69 citations in OpenAlex.
- A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance.CNS drugs · 2023Trial
- Patterns, motivations, and healthcare experiences of medical cannabis use among gender and sexuality diverse people in Australia: findings from the Cannabis as Medicine Survey 2022 (CAMS-22).Harm reduction journal · 2026Article
- Community pharmacists' practices and perspectives on deprescribing high-risk psychotropic medicines: National survey findings.British journal of clinical pharmacology · 2026Article
- Evolving health policy and regulatory oversight of medicinal cannabis in Australia: lessons for sustainable integration.Journal of cannabis research · 2026Review
- Does acute stress induced via cold water immersion increase blood THC concentrations in regular cannabis users?Psychopharmacology · 2025Article
- Consumer perspectives of accessing medicinal cannabis treatment from cannabis clinics versus generalist health settings in Australia.Journal of cannabis research · 2025Article
- Medicinal cannabis: is current use clinically justified?Internal medicine journal · 2025Review
- Factors associated with cannabis use disorder among Australians using prescribed and illicitly-sourced medical cannabis.Drug and alcohol dependence reports · 2025Article
- Clinicians' attitudes and knowledge of medicinal cannabis in opioid dependence treatment clinics in New South Wales, Australia.Journal of cannabis research · 2025Article
- Cannabis use among Dutch patients with a primary brain tumor.Neuro-oncology practice · 2025Article
- Understanding motives for illicit medicinal cannabis use: an exploratory analysis in a medical cannabis program.Journal of cannabis research · 2025Article
- Clinicians' Perspectives on Cannabis Use and Cannabis Treatment in Clients Undertaking Opioid Dependence Treatment.Drug and alcohol review · 2025Article
- Use of Medicinal Cannabis for Epilepsy in the Australian Community 2023-2024: A Cross-Sectional Survey.Journal of epilepsy research · 2025Article
- The prevalence and correlates of self-reported cannabis use for medicinal, dual and recreational motives in Australia: Findings from the National Drug Strategy Household Survey 2022/2023.Drug and alcohol review · 2025Article
- NSW cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development.Neuropsychopharmacology reports · 2025Article
- Evidence synthesis of medical cannabis research: current challenges and opportunities.European archives of psychiatry and clinical neuroscience · 2025Review
- An analysis of the cultivation, consumption and composition of home-grown cannabis following decriminalisation in the Australian Capital Territory.Scientific reports · 2025Article
- A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- The driving-related attitudes, beliefs and behaviours of cannabis users in the Australian Capital Territory following decriminalisation.Drug and alcohol review · 2025Article
- Optimization and Evaluation ofPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAustralia has had a framework for legal medicinal cannabis since 2016, yet prior online surveys in 2016 and 2018 indicated that most consumers continued to use illicit medical cannabis products. Regulatory data indicate an increase in the prescription of medicinal cannabis since 2019, and this survey examines consumer experiences of prescribed and illicit medical cannabis (MC) use in Australia.
methodsA cross-sectional anonymous online survey was administered September 2020 to January 2021. Recruitment via social media, professional and consumer forums, and medical practices. Participant eligibility: ≥ 18 years; used a cannabis product for self-identified medical reason(s) in the past year, and resident in Australia. Outcome measures included consumer characteristics, conditions treated, source and patterns of MC use, and perspectives on accessing MC.
resultsOf the 1600 participants (mean age 46.4 ± 14.3 years, 53% male), 62.4% (n = 999) reported using only illicit and 37.6% (n = 601) used prescribed MC in the past year. MC was used on a median of 28 (IQR: 12, 28) of the past 28 days and cost $AUD 74 ± 72 weekly (median = $40, IQR: $7, $100). Prescribed participants were more likely to treat pain conditions than those using illicit MC (52% v 40%, OR = 1.7, 1.3-2.1) and less likely to treat sleep conditions (6% v 11%, OR = 0.5, 0.3-0.8), with mental health conditions also a common indication in both groups (26%, 31%). Prescribed MC was consumed predominately by oral routes (72%), whereas illicit MC was most commonly smoked (41%). Prescribed MC was 'mainly THC' (26%), 'equal THC/CBD' (40%), 'mainly CBD' (31%) and 'uncertain' (3%), while 34% of those using illicit MC were 'uncertain' of the cannabinoid profile. Cost and difficulties finding medical practitioners to prescribe remain significant barriers to accessing prescribed MC, and few (10.8%) described the existing model for accessing prescribed MC as 'straightforward or easy'.
conclusionsThere has been a notable shift from illicit to prescribed MC by many consumers compared to prior surveys. Consumers using prescribed MC reported a range of advantages compared to illicit MC, including safer routes of administration, and greater certainty regarding access and composition of products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.